Abstract 2579
Background
NSR-SCC is a rare subset of bladder tumors distinct from urothelial carcinoma (UC). Most studies that have assessed molecular biomarkers in bladder cancer have been limited to UC. We aim to characterize the genomic profile of NSR-SCC and to correlate genomic alterations with survival outcomes.
Methods
This was a retrospective study of NSR-SCC patients (pts) at Princess Margaret Cancer Centre. Patient demographics, risk factors, disease characteristics, treatment modalities, and survival outcomes were collected for eligible pts. Genomic DNA and complementary DNA were analyzed using Oncomine® V3 assay, a targeted NGS platform. Overall survival (OS) was estimated by Kaplan-Meier (log-rank). Uni- (UVA) and multi-variate (MVA) analysis (Cox-regression) was used to evaluate the impact of patient and genomic characteristics on OS.
Results
We identified 11 pts with NSR-SCC from 2002-2017, with median age 71 years (range 46-86) and 7 were male. Nine pts had muscle invasive, 1 superficial stage and 1 distant metastasis. Nine pts had radical cystectomy and LN dissection. Eight pts had pT3 or pT4 with N0 and 6 were grade 2. Median OS was 12.5 months (95 % CI 7.7- 17.2 months). Common point mutations were identified in TERT (73%), TP53 (73%), PIK3CA (27%), CREBBP (18%), FBXW7 (18%), and PTEN (18%). Amplifications were identified in EGFR (18%), FGF3 (18%), CCND1 (18%), and FGF19 (18%). Additional mutations were detected at a frequency <10%. On UVA, only bladder irritants (e.g. prior radiation, urinary catheter, infection) were associated with improved OS (HR = 0.091; p = 0.031). A limited MVA didn’t identify any significant prognostic genomic abnormalities: TP53 (HR = 2.2; 95%CI: 0.3-17; p = 0.425), TERT (HR = 1.45; 95%CI: 0.2-10.2; p = 0.70) and PIK3CA (HR = 0.46; 95%CI: 0.1- 2.0; p = 0.31).
Conclusions
In this NSR-SCC series, we identified a number of actionable genomic alterations that may be targeted with drugs. No mutation was able to define different prognostic groups. Many of these aberrations were seen in UC. Biomarker driven studies in UC should consider enrollment of NSR-SCC pts who harbor these putative mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aaron Hansen.
Funding
Astellas.
Disclosure
A.G. Sacher: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self): Merck; Honoraria (self): Genentech-Roche. G. Kulkarni: Advisory / Consultancy: Janssen; Advisory / Consultancy: Astellas; Advisory / Consultancy: Roche; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Ferring; Advisory / Consultancy: Sanofi. A. Zlotta: Advisory / Consultancy: Sanofi; Advisory / Consultancy: Ferring; Advisory / Consultancy: Janssen. A.R. Hansen: Advisory / Consultancy, Research grant / Funding (self): Genentech; Advisory / Consultancy, Research grant / Funding (self): Roche; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy, Research grant / Funding (self): GSK; Advisory / Consultancy, Research grant / Funding (self): Bristol-Myers; Advisory / Consultancy, Research grant / Funding (self): Squibb; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy, Research grant / Funding (self): Boston Biomedical; Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract
2152 - Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations
Presenter: Istvan Miklos
Session: Poster Display session 3
Resources:
Abstract
4382 - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs
Presenter: Alberto Rodrigo
Session: Poster Display session 3
Resources:
Abstract
2465 - Towards a screening test for cancer by circulating DNA analysis
Presenter: Rita Tanos
Session: Poster Display session 3
Resources:
Abstract
3788 - Evaluation of a successful launch of the MammaPrint and BluePrint NGS kit
Presenter: Leonie Delahaye
Session: Poster Display session 3
Resources:
Abstract
3863 - Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning
Presenter: Pierre Heudel
Session: Poster Display session 3
Resources:
Abstract
1993 - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα
Presenter: Na Li
Session: Poster Display session 3
Resources:
Abstract
4281 - CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?——A multi-center prospective study in China
Presenter: Jun Luo
Session: Poster Display session 3
Resources:
Abstract
2268 - Classification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer
Presenter: Shinsuke Sasada
Session: Poster Display session 3
Resources:
Abstract
4035 - Prediction of benign and malignant breast masses using digital mammograms texture features
Presenter: Cui Yanhua
Session: Poster Display session 3
Resources:
Abstract